Tag:
Lyxumia
Latest Headlines
Latest Headlines
Sanofi stands up for diabetes therapy in crowded GLP-1 contest
Sanofi is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to build up its Lantus-led diabetes franchise amid relentless competition.
Sanofi R&D chief spotlights diabetes strategy amid Amylin bid buzz
In one of the worst kept secrets in the industry, Sanofi has been in the scrum of potential buyers forming around Amylin in recent weeks.
